#BEGIN_DRUGCARD DB08868

# AHFS_Codes:
FTY720

# ATC_Codes:
L04AA27

# Absorption:
The Tmax of fingolimod is 12-16 hours. 
Bioavailability: 93%

# Biotransformation:
3 main pathways: 
-reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod-phosphate.
-oxidative biotransformation mainly via the cytochrome P450 4F2 isoenzyme and subsequent fatty acid-like degradation to inactive metabolites.
-by formation of pharmacologically inactive non-polar ceramide analogs of fingolimod.

# Brand_Mixtures:
Not Available

# Brand_Names:
Gilenya

# CAS_Registry_Number:
162359-55-9

# ChEBI_ID:
63115

# Chemical_Formula:
C19H33NO2

# Chemical_IUPAC_Name:
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2013-04-28 14:17:47 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Immunosuppressive Agents

# Drug_Interactions:
Amiodarone	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Belimumab 	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
Disopyramide	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Dofetilide	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Dronedarone	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Ibutilide	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Ketoconazole	Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.
Procainamide	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Quinidine	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Sotalol	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.

# Drug_Reference:
23609767	An X, Kezuka T, Usui Y, Matsunaga Y, Matsuda R, Yamakawa N, Goto H: Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod. J Neuroophthalmol. 2013 Apr 19.
23609782	Ali R, Nicholas RS, Muraro PA: Drugs in Development for Relapsing Multiple Sclerosis. Drugs. 2013 Apr 23.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.178

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Fingolimod

# HET_ID:
Not Available

# Half_Life:
6-9 days

# InChI_Identifier:
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

# InChI_Key:
InChIKey=KKGQTZUTZRNORY-UHFFFAOYSA-N

# Indication:
Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D10001

# LIMS_Drug_ID:
8878

# Mechanism_Of_Action:
Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
307.4708

# Molecular_Weight_Mono:
307.251129305

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Fingolimod causes a transient reduction in heart rate and AV conduction at treatment initiation.
Potential to prolong the QT interval.
Effects on immune cell numbers in the blood- decreased lymphocyte counts.
Mild decrease in the neutrophil count- about 80% of original pre-therapy count.
Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively.
IgG titers were decreased by 45% and 50%, in response to KLH and PPV.
The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on fingolimod 0.5 mg daily, compared to placebo. Immunologic responses were further decreased with fingolimod 1.25 mg (a dose higher than recommended for MS).
Single fingolimod doses â‰¥5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance.

# Predicted_LogP_Hydrophobicity:
4

# Predicted_LogS:
-4.7

# Predicted_Water_Solubility:
6.90e-03 g/l

# Primary_Accession_No:
DB08868

# Protein_Binding:
>99.7%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/gilenya-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2-amino-2-(2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride
FTY-720A
FTY720
Fingolimod HCl
Fingolimod hydrochloride
Gilenia

# Synthesis_Reference:
Not Available

# Toxicity:
Bradyarrhythmia and Atrioventricular Blocks
Risk of infections
Macular Edema
Respiratory Effects
Hepatic Effects  
Fetal Risk
Blood Pressure Effects
Immune System Effects Following Fingolimod Discontinuation

# Update_Date:
2013-04-28 21:55:19 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Fingolimod

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_3_ID:
6013

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_4_ID:
7278

# Phase_1_Metabolizing_Enzyme_4_Name:
Leukotriene-B(4) omega-hydroxylase 1

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P78329

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_5_ID:
7279

# Phase_1_Metabolizing_Enzyme_5_Name:
Sphingosine kinase 1

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
Q9NYA1

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_6_ID:
7280

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 4F12

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
Not Available

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
Q9HCS2

# Drug_Target_1_Cellular_Location:
Membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
23579456	Bhabak KP, Arenz C: Novel drugs targeting sphingolipid metabolism. Handb Exp Pharmacol. 2013;215:187-96. doi: 10.1007/978-3-7091-1368-4_10.
23579459	Zu Heringdorf DM, Ihlefeld K, Pfeilschifter J: Pharmacology of the sphingosine-1-phosphate signalling system. Handb Exp Pharmacol. 2013;215:239-53. doi: 10.1007/978-3-7091-1368-4_13.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
EDG8

# Drug_Target_1_GenBank_ID_Gene:
AF331840

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
S1PR5

# Drug_Target_1_Gene_Sequence:
>1197 bp
ATGGAGTCGGGGCTGCTGCGGCCGGCGCCGGTGAGCGAGGTCATCGTCCTGCATTACAAC
TACACCGGCAAGCTCCGCGGTGCGCGCTACCAGCCGGGTGCCGGCCTGCGCGCCGACGCC
GTGGTGTGCCTGGCGGTGTGCGCCTTCATCGTGCTAGAGAATCTAGCCGTGTTGTTGGTG
CTCGGACGCCACCCGCGCTTCCACGCTCCCATGTTCCTGCTCCTGGGCAGCCTCACGTTG
TCGGATCTGCTGGCAGGCGCCGCCTACGCCGCCAACATCCTACTGTCGGGGCCGCTCACG
CTGAAACTGTCCCCCGCGCTCTGGTTCGCACGGGAGGGAGGCGTCTTCGTGGCACTCACT
GCGTCCGTGCTGAGCCTCCTGGCCATCGCGCTGGAGCGCAGCCTCACCATGGCGCGCAGG
GGGCCCGCGCCCGTCTCCAGTCGGGGGCGCACGCTGGCGATGGCAGCCGCGGCCTGGGGC
GTGTCGCTGCTCCTCGGGCTCCTGCCAGCGCTGGGCTGGAATTGCCTGGGTCGCCTGGAC
GCTTGCTCCACTGTCTTGCCGCTCTACGCCAAGGCCTACGTGCTCTTCTGCGTGCTCGCC
TTCGTGGGCATCCTGGCCGCGATCTGTGCACTCTACGCGCGCATCTACTGCCAGGTACGC
GCCAACGCGCGGCGCCTGCCGGCACGGCCCGGGACTGCGGGGACCACCTCGACCCGGGCG
CGTCGCAAGCCGCGCTCGCTGGCCTTGCTGCGCACGCTCAGCGTGGTGCTCCTGGCCTTT
GTGGCATGTTGGGGCCCCCTCTTCCTGCTGCTGTTGCTCGACGTGGCGTGCCCGGCGCGC
ACCTGTCCTGTACTCCTGCAGGCCGATCCCTTCCTGGGACTGGCCATGGCCAACTCACTT
CTGAACCCCATCATCTACACGCTCACCAACCGCGACCTGCGCCACGCGCTCCTGCGCCTG
GTCTGCTGCGGACGCCACTCCTGCGGCAGAGACCCGAGTGGCTCCCAGCAGTCGGCGAGC
GCGGCTGAGGCTTCCGGGGGCCTGCGCCGCTGCCTGCCCCCGGGCCTTGATGGGAGCTTC
AGCGGCTCGGAGCGCTCATCGCCCCAGCGCGACGGGCTGGACACCAGCGGCTCCACAGGC
AGCCCCGGTGCACCCACAGCCGCCCGGACTCTGGTATCAGAACCGGCTGCAGACTGA

# Drug_Target_1_General_Function:
Involved in lysosphingolipid and lysophosphatidic acid receptor activity

# Drug_Target_1_General_References:
12044878	Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S: Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002 Jun 5;520(1-3):97-101.

# Drug_Target_1_HGNC_ID:
HGNC:14299

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4199

# Drug_Target_1_Locus:
19p13.2

# Drug_Target_1_Molecular_Weight:
41776

# Drug_Target_1_Name:
Sphingosine 1-phosphate receptor Edg-8

# Drug_Target_1_Number_of_Residues:
398

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Sphingosine 1-phosphate receptor Edg-8
MESGLLRPAPVSEVIVLHYNYTGKLRGARYQPGAGLRADAVVCLAVCAFIVLENLAVLLV
LGRHPRFHAPMFLLLGSLTLSDLLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
ASVLSLLAIALERSLTMARRGPAPVSSRGRTLAMAAAAWGVSLLLGLLPALGWNCLGRLD
ACSTVLPLYAKAYVLFCVLAFVGILAAICALYARIYCQVRANARRLPARPGTAGTTSTRA
RRKPRSLALLRTLSVVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSL
LNPIIYTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCLPPGLDGSF
SGSERSSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. Is coupled to both the G(i/0)alpha and G(12) subclass of heteromeric G-proteins (By similarity). May play a regulatory role in the transformation of radial glial cells into astrocytes and may affect proliferative activity of these cells

# Drug_Target_1_SwissProt_ID:
Q9H228

# Drug_Target_1_SwissProt_Name:
S1PR5_HUMAN

# Drug_Target_1_Synonyms:
Endothelial differentiation sphingolipid G-protein-coupled receptor 8
S1P5
Sphingosine 1-phosphate receptor 5

# Drug_Target_1_Theoretical_pI:
9.98

# Drug_Target_1_Transmembrane_Regions:
41-61
71-91
112-132
152-172
193-213
253-273
288-308

#END_DRUGCARD DB08868
